Journal
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
Volume 20, Issue -, Pages S17-S23Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ijir.2008.18
Keywords
male sexual dysfunction; erectile dysfunction; treatment; bremelanotide
Categories
Ask authors/readers for more resources
Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available